Author + information
- Colleen McHorneya,b,
- Veronica Ashtona,b,
- François Lalibertéa,b,
- Guillaume Germaina,b,
- Willy Wynanta,b,
- Concetta Criveraa,b,
- Jeffrey Scheina,b,
- Patrick Lefebvrea,b and
- Eric Petersona,b
Background: In non-valvular atrial fibrillation (NVAF) patients, persistence on oral anticoagulants (OACs) is important to prevent potentially severe adverse events.
Objective: To evaluate persistence on therapy and to compare time to discontinuation among NVAF patients using OACs.
Methods: IMS Health Real-World Data Adjudicated Claims from 01/2011-06/2015 were analyzed. Patients with ≥2 dispensings of rivaroxaban, apixaban, dabigatran, or warfarin ≥180 days apart (the first was termed as the index date), >60 days of supply, ≥6 months of pre-index eligibility without prior use of the index OAC agent, ≥1 AF diagnosis pre or at index date, and without valvular involvement were included. Discontinuation was defined as a gap of >30 days (15 and 45 days used as sensitivities) between the end of a dispensing and the next fill if any. Kaplan-Meier rates of persistence were evaluated. Cox models adjusting for baseline confounders were used to compare the time to discontinuation between different OAC users.
Results: A total of 13,645 rivaroxaban, 6,304 apixaban, 3,360 dabigatran, and 13,366 warfarin patients were identified. Compared with other OACs rivaroxaban users had a higher persistence and were significantly less likely to discontinue therapy after adjustments (Table). Results of sensitivity tests also found less discontinuation for patients taking rivaroxaban.
Conclusions: Among NVAF patients rivaroxaban users were significantly less likely to discontinue therapy compared with other OAC users.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Antithrombotic Therapy in Ischemic Heart Disease
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1252-306
- 2017 American College of Cardiology Foundation